Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN-Reference-Cited by-同舟云学术

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN

Published:2018-05-16 Issue:4 Volume:5 Page:592-602
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Pitt Bertram¹,Bakris George L.²,Weir Matthew R.³,Freeman Mason W.⁴,Lainscak Mitja⁵,Mayo Martha R.⁶,Garza Dahlia⁶,Zawadzki Rezi⁶,Berman Lance⁶,Bushinsky David A.⁷

Affiliation:

1. Department of Internal Medicine; University of Michigan School of Medicine; Ann Arbor MI USA

2. Department of Medicine; University of Chicago Medicine; Chicago IL USA

3. Division of Nephrology, Department of Medicine; University of Maryland School of Medicine; Baltimore MD USA

4. Department of Medicine; Massachusetts General Hospital, Harvard University; Boston MA USA

5. Division of Cardiology; General Hospital Murska Sobota; Murska Sobota Slovenia

6. Relypsa, Inc., a Vifor Pharma Group Company; Redwood City CA USA

7. Division of Nephrology, Department of Medicine; University of Rochester School of Medicine; Rochester NY USA

Funder

Relypsa, Inc., a Vifor Pharma Group Company

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ehf2.12292/fullpdf

Reference35 articles.

1. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America;Yancy;J Am Coll Cardiol,2016

2. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC;Ponikowski;Eur J Heart Fail,2016

3. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction;Pitt;N Engl J Med,2003

4. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators;Pitt;N Engl J Med,1999

5. Eplerenone in patients with systolic heart failure and mild symptoms;Zannad;N Engl J Med,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial;Kidney International Reports;2024-08

2. A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group;Journal of the Saudi Heart Association;2024-06-01

3. Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study;Journal of Nephrology;2024-02-06

4. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study;Kidney Medicine;2024-01

5. Renin Angiotensin Aldosterone System Blockers;Hypertension;2024